MedTrace Logo

Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

NCT04868773 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-04-24

No results posted yet for this study

Summary

This is a phase I clinical trial assessing the safety and recommended phase II dose of cabozantinib in combination with trifluridine/tipiracil (TAS102) in patients with metastatic colorectal carcinoma (mCRC).

Conditions

Interventions

DRUG

Cabozantinib

Oral cabozantinib

DRUG

TAS-102

Oral TAS-102 (trifluridine and tipiracil)

Sponsors & Collaborators

  • University of California, Irvine

    lead OTHER

Principal Investigators

  • Farshid Dayyani, MD · Chao Family Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-16
Primary Completion
2023-08-29
Completion
2024-04-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04868773 on ClinicalTrials.gov